|
 |
| gu/prostate |
Lee, W., DeSilvio, M., Lawton, C., Gillin, M., Morton, G., Firat, S., Baikadi, M., Kuettel, M., Greven, K. and Sandler, H.: Is Postimplant Dosimetry Associated with Late Morbidity? A Secondary Analysis of RTOG P-0019. Multidisciplinary Prostate Cancer Symposium, Orlando, FL, Multi Prostate Cancer Sym Booklet, pg. Abs. #96, 2005. |
0019 |
RT/brachy |
 |
| gu/prostate |
Roach, M., DeSilvio, M., Thomas Jr., C., Valicenti, R., Asbell, S., Lawton, C. and Shipley, W.: Field Size and Progression Free Survival (PFS) After Neoadjuvant Hormonal Therapy (HT) and Radiotherapy (RT) for Prostate Cancer:Secondary Analysis of RTOG 9413. Multidisciplinary Prostate Cancer Symposium, Orlando, FL, Multi Prostate Cancer Sym Booklet, pg. Abs. #87, 2005. |
9413 |
rt/neoadjuvant hormones |
|
| gu/prostate |
Lawton, C., DeSilvio, M., Lee, W., Gomella, L., Grignon, D., Gillin, M., Morton, G., Pisansky, T. and Sandler, H.: Correlating Prostate Seed Implant Quality With Clinical Outcomes For Patients Treated On RTOG Protocol 98-05 (A Multi-Institutional Phase II Trial Of Transrectal Ultrasound Guided Prostate Seed Implant For Localized Prostate Cancer). Multidisciplinary Prostate Cancer Symposium, Orlando, FL, Multi Prostate Cancer Sym Booklet, pg. Abs. #90, 2005. |
9805 |
gu/prostate |
|
| gu/prostate |
Che, M., DeSilvio, M., Pollack, A., Grignon, D., Venkatesan, V., Hanks, G. and Sandler, H.: Prognostic Value of Abnormal P53 Expression in Locally Advanced Prostate Cancer Treated with Androgen Deprivation and Radiotherapy: A Study Based on RTOG 9202. Multidisciplinary Prostate Cancer Symposium, Orlando, FL, Multi Prostate Cancer Sym Booklet, pg. Abs. #62, 2005. |
9202 |
p53/rt/horm |
|
| gu/prostate |
Michalski, J., Winter, K., Roach III, M., Markoe, A., Sandler, H., Ryu, J., Parliament, M., Purdy, J., Valicenti, R. and Cox, J.: Clinical Outcome of Patients Treated with 3D Conformal Radiation Therapy 3D-CRT for Prostate Cancer on RTOG 9406. Multidisciplinary Prostate Cancer Symposium, Orlando, FL, Multi Prostate Cancer Sym Booklet, pg. Abs. #84, 2005. |
9406 |
RT/3D |
|
| gu/prostate |
Valicenti, R., DeSilvio, M., Hanks, G., Porter, A., Brereton, H., Shipley, W. and Sandler, H.: Surrogate Endpoint for Prostate Cancer-specific Survival: Validation from an Analysis of Radiation Therapy Oncology Group Protocol 92-02. Proc Am Soc Clin Oncol (ASCO), Orlando, FL, J Clin Oncol, [23] (16S) pg. 390s, Abs. #4549, 2005. |
9202 |
gleason/horm |
|
| gu/prostate |
Pollack, A., DeSilvio, M., Khor, L.-Y., Hammond, E., Rosenthal, S. and Asbell, S.: MDM2 Expression Predicts For Prostate Cancer Outcome After Radiotherapy And Androgen Deprivation: An Analysis of RTOG 92-02. Amer Radium Society (ARS), Barcelona, Spain, ARS Meeting Booklet, pg. Abs. #86, 2005. |
9202 |
MDM2 |
|
| gu/prostate |
Torres-Roca, J., DeSilvio, M., Mora-Diaz, L., Hammond, E., Ahmad, N., Jove, R., Forman, J., Lee, R., Sandler, H. and Pollack, A.: Stat3 as a Correlate of Distant Metastasis in RTOG 86-10. Proc Am Soc Clin Oncol (ASCO), Orlando, FL, J Clin Oncol, [23] (16S) pg. 416s, Abs. #4656, 2005. |
8610 |
STAT3 |
|
| gu/prostate |
Lawton, C., DeSilvio, M., Roach III, M., Uhl, V., Krisch, R., Seider, M., Rotman, M., Jones, C., Asbell, S., Valicenti, R., Han, S. and Thomas, C.: An Update of the Phase III Trial Comparing Whole-Pelvic (WP) to Prostate Only (PO) Radiotherapy and Neoadjuvant to Adjuvant Total Androgen Suppression (TAS): Updated Analysis of RTOG 94-13. Proc Amer Soc Thera Rad Onc (ASTRO), Denver, CO, Int J Radiat Oncol Biol Phys, [63] (Suppl. 1) pg. S19, Abs. #32, 2005. |
9413 |
rt, horm |
|
| gu/prostate |
Zhang, M., Ho, A., Hammond, E., Roach III, M., Sause, W., Pilepich, M., Shipley, W., Sandler, H., Pollack, A. and Chakravarti, A.: The Prognostic Value of Surviving in Locally Advanced Prostate Cancer: A Study Based on RTOG 8610. Proc Amer Soc Thera Rad Onc (ASTRO), Denver, CO, Int J Radiat Oncol Biol Phys, [63] (Suppl. 1) pg. S18, Abs. #31, 2005. |
8610 |
survivin |
|
| gu/prostate |
Zhai, G., Ho, A., Hammond, E., Fontanesi, J., Rotman, M., Pilepich, M., Shipley, W., Sandler, H., Pollack, A., Zhang, H. and Chakravarti, A.: Phospho-AKT Expression and Prognosis of Locally Advanced Prostate Cancer: A Study Based on RTOG 8610. Proc Amer Soc Thera Rad Onc (ASTRO), Denver, CO, Int J Radiat Oncol Biol Phys, [63] (Suppl. 1) pg. S319, Abs. #2152, 2005. |
8610 |
AKT |
|
| gu/prostate |
Sandler, H., DeSilvio, M., Pienta, K., Hug, E., Asbell, S., Rajan, R., Kerlin, K., Michalski, J. and Rosenthal, S.: Preliminary Analysis of RTOG 9902: Increased Toxicity Observed with the Use of Adjuvant Chemotherapy. Proc Amer Soc Thera Rad Onc (ASTRO), Denver, CO, Int J Radiat Oncol Biol Phys, [63] (Suppl. 1) pg. S123, Abs. #203, 2005. |
9902 |
rt, horm, chemo |
|
| gu/prostate |
Chakravarti, A., DeSilvio, M., Zhang, M., Grignon, D., Rosenthal, S., Asbell, S., Hanks, G., Sandler, H., Pollack, A., Zhai, G. and Shipley, W.: The Prognostic Value of p16 Expression in Locally Advanced Prostate Cancer: A Study Based on RTOG 92-02. Proc Amer Soc Thera Rad Onc (ASTRO), Denver, CO, Int J Radiat Oncol Biol Phys, [63] (Suppl. 1) pg. S17-S18, Abs. #30, 2005. |
9202 |
p16/rt, horm |
|
| gu/prostate |
Pollack, A., DeSilvio, M., Khor, L.-Y., Hammond, E., Al-Saleem, T., Grignon, D., Che, M., Varagur, V., Byhardt, R., Rotman, M., Hanks, G. and Sandler, H.: MDM2 Expression Is Independent of P53 and Ki-67 in Predicting Prostate Cancer Outcome: An Analysis of RTOG 92-02. Proc Amer Soc Thera Rad Onc (ASTRO), Denver, CO, Int J Radiat Oncol Biol Phys, [63] (Suppl. 1) pg. S17, Abs. #29, 2005. |
9202 |
ki67, MDM2, p53 |
|
| gu/prostate |
Thompson, I., Tangen, C., Miller, G., Lucia, M. S., Troyer, D., Paradelo, J., Chin, J., Messing, E., Canby-Hagino, E., Forman, J. and Crawford, E. D.: Adjuvant Radiotherapy For Pathologic T3 Prostate Cancer: Results Of A Randomized, Prospective Clinical Trial With Metastasis-Free Survival Endpoint. Amer Urology Assoc (AUA), San Antonio, TX, J of Urology, pg. Abs. #1665, 2005. |
9019 |
rt |
|
| gu/prostate |
Swanson, G., Thompson, I., Tangen, C., Miller, G., Lucia, M. S., Troyer, D., Paradelo, J., Chin, J., Messing, E., Canby-Hagino, E., Forman, J. and Crawford, E. D.: Phase III Randomized Study of Adjuvant Radiation Therapy versus Observation in Patients with Pathologic T3 Prostate Cancer (SWOG 8794). Proc Amer Soc Thera Rad Onc (ASTRO), Denver, CO, Int J Radiat Oncol Biol Phys, [63] (Suppl. 1) pg. S1, Abs. #1, 2005. |
9019 |
rt |
|
| gu/prostate |
Chakravarti, A., Winter, K., Wu, C.-L., Kaufman, D., Hammond, E., Parliament, M., Tester, W., Hagan, M., Grignon, D., Heney, N., Pollack, A., Sandler, H. and Shipley, W.: Expression of the Epidermal Growth Factor Receptor and Her-2 are Predictors of Favorable Outcome and Reduced Complete Response Rates, Respectively, in Patients with Muscle-Invading Bladder Cancers Treated by Concurrent Radiation And Cisplatin-Based Chemotherapy: A Report from The Radiation Therapy Oncology Group. Int J Radiat Onco Biol Phys, 62 (2):309-317, 2005. |
8802,8903,9506,9706 |
p16/pRB/horm |
|
| gu/prostate |
Pilepich, M., Winter, K., Lawton, C., Krisch, R. E., Wolkov, H., Movsas, B., Hug, E., Asbell, S. and Grignon, D.: Androgen Suppression Adjuvant To Definitive Radiotherapy In Prostate Carcinoma - Long-Term Results of Phase III RTOG 85-31. Int J Radiat Onco Biol Phys, 61 (5):1285-1290, 2005. |
8531 |
horm |
|
| gu/prostate |
Konski, A., Sherman, E., Krahn, M., Bremner, K., Beck, J., Watkins Bruner, D. and Pilepich, M.: Economic Analysis of a Phase III clinical Trial Evaluating the Addition of Total Androgen Suppression to Radiation Versus Radiation Alone for Locally Advanced Prostate Cancer (Radiation Therapy Oncology Group protocol 86-10). Int J Radiat Onco Biol Phys, 63 (3):788-794, 2005. |
8610 |
Outcomes/ECON |
|
| gu/prostate |
Feigenberg, S., Lee, W. R., DeSilvio, M., Winter, K., Pisansky, T., Watkins-Bruner, D., Lawton, C., Morton, G., Baikadi, M. and Sandler, H.: Health-Related Quality of Life In Men Receiving Prostate Brachytherapy on RTOG 98-05. Int J Radiat Onco Biol Phys, 62 (4):956-964, 2005. |
9805 |
Outcomes/QOL/RT/brachy |
|
| gu/prostate |
Khor, L.-Y., DeSilvio, M., Al-Saleem, T., Hammond, E., Sause, W., Pilepich, M., Okunieff, P., Sandler, H. and Pollack, A.: MDM2 As a Predictor of Prostate Cancer Outcome: An Analysis of RTOG 8610. Cancer, 104 (5):962-967, 2005. |
8610 |
MDM2/horm/rt |
|
| gu/prostate |
Zietman, A., DeSilvio, M., Slater, J., Rossi Jr., C., Miller, D., Adams, J. and Shipley, W.: Comparison of Conventional-Dose vs High-Dose Conformal Radiation Therapy in Clinically Localized Adenocarcinoma of the Prostate. JAMA, 294 (10):1233-1239, 2005. |
9509 |
proton none |
|
| gu/prostate |
Michalski, J., Winter, K., Purdy, J., Parliament, M., Wong, H., Perez, C., Roach III, M., Bosch, W. and Cox, J.: Toxicity After Three-Dimensional Radiotherapy for Prostate Cancer on RTOG 9406 Dose Level V. Int J Radiat Onco Biol Phys, 62 (3):706-713, 2005. |
9406 |
RT/3D |
|
| gu/bladder |
Kaufman, D., Winter, K., Shipley, W., Althausen, A., Hug, E., Toonkel, L. and H, S.: Muscle-Invading Bladder Cancer, RTOG Protocol 99-06: Initial Report of a Phase I/II trial of Selective Bladder-Conservation Employing TURBT, Accelerated Irrdiation Sensitized with Cisplatin and Paclitaxel Followed by Adjuvant Cisplatin and Gemcitabine Chemotherapy. Proc Am Soc Clin Oncol (ASCO), Orlando, FL, J Clin Oncol, [23] (16S) pg. 379s, Abs. #4506, 2005. |
9906 |
chemo |
|
| gu/prostate |
Amin, M., Grignon, D., Humphrey, P. and Srigley, J.: Gleason Grading of Prostate Cancer: A Contemporary Approach. In Library of Congress Cataloging ed.) Lippincott Williams & Wilkins, Philadelphia, PA, pg. 1-116, 2004. |
gleason |
path |
|
| gu/prostate |
Roach III, M., Winter, K., Michalski, J., Cox, J., Purdy, J., Bosch, W., Lin, X. and Shipley, W.: Penile Bulb Dose and Impotence After Three-Dimensional Conformal Radiotherapy for Prostate Cancer on RTOG 9406: Findings From A Prospective, Multi-Institutional, Phase I/II Dose-Escalation Study. Int J Radiat Onco Biol Phys, 60 (5):1351-1356, 2004. |
9406 |
RT/3D |
|
| gu/prostate |
Lawton, C., Winter, K., Grignon, D. and Pilepich, M.: Androgen Suppression plus Radiation versus Radiation Alone for Patients with D1 (pN+) Adenocarcinoma of the Prostate (Updated Results Based on a National Prospective Randomized Trial, RTOG 85-31). J Clin Oncol, 23 (4):800-807, 2005. |
8531 |
horm |
|
| gu/prostate |
Li, R., Heydon, K., Hammond, E., Grignon, D., Roach III, M., Wolkov, H., Sandler, H., Shipley, W. and Pollack, A.: Ki-67 Staining Index Predicts Distant Metastasis and Survival in Locally Advanced Prostate Cancer Treated with Radiotherapy: An Analysis of Patients in RTOG Protocol 86-10. Clin Cancer Research, 10 4118-4124, 2004. |
8610 |
marker/Ki-67
horm/rt |
|
| gu/prostate |
Lawton, C., DeSilvio, M., Lee, W., Gomella, D., Grignon, D., Gillin, M., Morton, G., Pisansky, T. and Sandler, H.: Results of a Prospective Multi-Institutional Phase II Trial (RTOG 98-05) of Transrectal Ultrasound Guided Permanent Radioactive Implantation of the Prostate for Definitive Management of Localized Adenocarcinoma of the Prostate. Proc Amer Soc Thera Rad Onc (ASTRO), Atlanta, GA, Int J Radiat Oncol Biol Phys, [60] (1) pg. S184-185, Abs. #90, 2004. |
9805 |
RT/brachy |
|
| gu/prostate |
Konski, A., Watkins-Bruner, D., Brereton, H. and Hanks, G.: Long-Term Hormone Therapy in addition to Radiation is Cost-Effective in the Treatment of Patients with Locally Advanced Prostate Cancer: An Economic Analysis of Radiation Therapy Oncology Group (RTOG) protocol 92-02. Amer Radium Society (ARS), Napa Valley, CA, Proceedings from ARS Booklet, pg. 25, Abs. #24, 2004. |
9202 |
gleason
horm |
|
| gu/prostate |
Roach, M., DeSilvio, M., Thomas Jr., C., Valicenti, R., Asbell, S., Lawton, C. and Shipley, W.: Progression Free Survival (PFS) after Whole-Pelvic (WP) vs. Mini-Pelvic (MP) or Prostate Only (PO) Radiotherapy (RT): A Subset Analysis of RTOG 9413, a Phase III Prospective Randomized Using Neoadjuvant and Concurrent (N&CHT). Proc Amer Soc Thera Rad Onc (ASTRO), Atlanta, GA, Int J Radiat Oncol Biol Phys, [60] (1) pg. S264-265, Abs. #1014, 2004. |
9413 |
horm/rt |
|
| gu/prostate |
Abdel-Wahab, M., Berkey, B., Krishan, A., O'Brien, T., Hammond, E., Roach III, M., Lawton, C., Pilepich, M., Markoe, A. and Pollack, A.: Influence of Number of CAG Repeats on Local Control in the RTOG 86-10 Protocol. Proc Amer Soc Thera Rad Onc (ASTRO), Atlanta, GA, Int J Radiat Oncol Biol Phys, [60] (1) pg. S326, Abs. #1118, 2004. |
8610 |
marker/CAG
horm/rt |
|
| gu/prostate |
Michalski, J., Winter, K., Roach III, M., Markoe, A., Sandler, H., Ryu, J., Parliament, M., Purdy, J., Valicenti, R. and Cox, J.: Clinical Outcome of Patients Treated with 3D Conformal Radiation Therapy 3D-CRT for Prostate Cancer on RTOG 94-06. Proc Amer Soc Thera Rad Onc (ASTRO), Atlanta, GA, Int J Radiat Oncol Biol Phys, [60] (1) pg. S169, Abs. #66, 2004. |
9406 |
RT/3D |
|
| gu/prostate |
Zietman, A., DeSilvio, M., Slater, J., Rossi, C., Yonemoto, L., Slater, J., Berkey, B., Adams, J. and Shipley, W.: A Randomized Trial Comparing Conventional Dose (70.2GyE) and High-Dose (79. 2GyE) Conformal Radiation in Early Stage Adenocarcinoma of the Prostate: Results of an Interim Analysis of PROG 95-09. Proc Amer Soc Thera Rad Onc (ASTRO), Atlanta, GA, Int J Radiat Oncol Biol Phys, [60] (1) pg. S131-132, Abs. #4, 2004. |
9509 |
proton |
|
| gu/prostate |
Khor, L., DeSilvio, M., Al-Saleem, T., Hammond, E., Sause, W., Pilepich, M., Okunieff, P., Sandler, H. and Pollack, A.: MDM2 As A Predictor of Prostate Cancer Outcome: An Analysis of RTOG 8610. Proc Amer Soc Thera Rad Onc (ASTRO), Atlanta, GA, Int J Radiat Oncol Biol Phys, [60] (1) pg. S472-473, Abs. #2227, 2004. |
8610 |
MDM
horm/rt |
|
| gu/prostate |
Bonner, J., Buchsbaum, D., Rogers, B., Grizzle, W., Trummell, H., Curiel, D., Fiveash, J., Ove, R. and Raisch, K.: Adenoviral Vector-Mediated Augmentation of Epidermal Growth Factor Receptor (EGFr) Enhances the Radiosensitization Properties of Anti-EGFr Treatment in Prostate Cancer Cells. Int J Radiat Onco Biol Phys, 58 (3):950-958, 2004. |
|
EGFR |
|
| gu/prostate |
Michalski, J., Winter, K., Purdy, J., Perez, C., Ryu, J., Parliament, M., Valicenti, R., Roach III, M., Sandler, H., Markoe, A. and Cox, J.: Toxicity After Three-Dimensional Radiotherapy for Prostate Cancer with RTOG 9406 Dose Level IV. Int J Radiat Onco Biol Phys, 58 (3):735-742, 2004. |
9406 |
3D |
|
| gu/prostate |
Pollack, A., DeSilvio, M., Khor, L., Li, R., Al-Saleem, T., Hammond, E., Venkatesan, V., Lawton, C., Roach III, M., Shipley, W., Hanks, G. and Sandler, H.: Ki-67 Staining is a Strong Predictor of Distant Metastasis and Mortality for Men with Prostate Cancer Treated with Radiotherapy Plus Androgen Deprivation: Radiation Therapy Oncology Group Trial 92-02. J Clin Oncol, 22 (11):2133-2140, 2004. |
9202 |
Ki-67
horm/rt |
|
| gu/prostate |
Pollack, A., DeSilvio, M., Khor, L., Al-Saleem, T., Hammond, E., Li, R., Roach III, M., SA, R., Movsas, B., Shipley, W., Hanks, G. and Sandler, H.: Recursive Partitioning Analysis of Predictors of Distant Metastasis for Men with Prostate Cancer Treated with Radiotherapy and Androgen Deprivation on RTOG 9202: The Impact of Ki-67. Amer Urology Assoc (AUA), San Francisco, CA, J of Urology, (May 8-13, 2004) pg. Abs. #597, 2004. |
9202 |
Ki-67
horm/rt |
|
| gu/prostate |
Lee, W., DeSilvio, M., Lawton, C., Gillin, M., Morton, G., Firat, S., Baikadi, M., Kuettel, M., Greven, K. and Sandler, H.: A Phase II Study of External Beam Radiation Therapy Combined With Permanent Source Brachytherapy for Intermediate Risk Clinically Localized Adenocarcinoma of the Prostate: Preliminary Results of RTOG P-0019. Proc Am Soc Clin Oncol (ASCO), New Orleans, LA, J Clin Oncol, [23] (June 5-8, 2004) pg. 397, Abs. #4568, 2004. |
0019 |
brachy, rt |
|
| gu/prostate |
Konski, A., Bruner, D., Brereton, H. and Hanks, G.: Long-Term Hormone Therapy in addition to Radiation is Cost-Effective in the Treatment of Patients with Locally Advanced Prostate Cancer: An Economic Analysis of Radiation Therapy Oncology Group (RTOG) protocol 92-02. Amer Radium Society (ARS), Napa Valley, CA, Proceedings from ARS Booklet, pg. 4, Abs. #24, 2004. |
9202 |
gleason
horm |
|
| gu/bladder |
Hagan, M., Winter, K., Kaufman, D., Wajsman, Z., Zietman, A., Heney, N., Toonkel, L., Jones, C., Roberts, J. and Shipley, W.: RTOG 97-06: Initial Report of a Phase I–II trial of Selective Bladder Conservation Using TURBT, Twice-Daily Accelerated Irradiation Sensitized with Cisplatin, and Adjuvant MCV Combination Chemotherapy. Int J Radiat Onco Biol Phys, 57 (3):665-672, 2003. |
9706 |
gu/bladder
rt/chemo |
|
| gu/prostate |
Michalski, J., Winter, K., Purdy, J., Parliament, M., Wong, H., Perez, C., Roach III, M., Bosch, W. and Cox, J.: Toxicity Following 3D Radiation Therapy for Prostate Cancer on RTOG 94-06 Dose Level V. Proc Am Soc Thera Rad Oncol (ASTRO), Salt Lake City, UT, Int J Radiat Oncol Biol Phys, [57] (2) pg. S151, Abs. #46, 2003. |
9406 |
gu/prostate
3D |
|
| gu/prostate |
Pollack, A., DeSilvio, M., Khor, L., Li, R., Al-Saleem, T., Hammond, E., Venkatesan, V., Byardt, R., Hanks, G., Roach III, M., Shipley, W. and Sandler, H.: Ki-67 Staining Is a Strong Predictor of Patient Outcome for Prostate Cancer Patients Treated with Androgen Deprivation Plus Radiotherapy: An Analysis of RTOG 92-02. Proc Am Soc Thera Rad Oncol (ASTRO), Salt Lake City, UT, Int J Radiat Oncol Biol Phys, [57] (2) pg. S200-201, Abs. #126, 2003. |
9202 |
gu/prostate
Ki-67
horm/rt |
|
| gu/prostate |
Hughes, L., Heydon, K., Edmonds, P., Roach III, M., Wolkov, H., Shah, S., Pollack, A., Hammond, E. and Dicker, A.: Vascular Endothelial Growth Factor (VEGF) Expression in Locally Advanced Prostate Cancer (LAPC): Secondary Analysis of Radiation Therapy Oncology Group (RTOG) 86-10. Proc Am Soc Thera Rad Oncol (ASTRO), Salt Lake City, UT, Int J Radiat Oncol Biol Phys, [57] (2) pg. S201-202, Abs. #128, 2003. |
8610 |
gu/prostate
VEGF/MVD
horm/path |
|
| gu/prostate |
Konski, A., Sherman, E., Krahn, M., Bremner, K., Beck, J., Watkins Bruner, D. and Pilepich, M.: Monte Carlo Simulation of a Markov Model for a Phase III Clinical Trial Evaluating the Addition of Total Androgen Suppression (TAS) To Radiation Versus Radiation Alone for Locally Advanced Prostate Cancer (RTOG 86-10). Proc Am Soc Thera Rad Oncol (ASTRO), Salt Lake City, UT, Int J Radiat Oncol Biol Phys, [57] (2) pg. S215-216, Abs. #151, 2003. |
8610 |
gu/prostate
ECON |
|
| gu/prostate |
Hanks, G., Pajak, T., Porter, A., Grignon, D., Brereton, H., Venkatesan, V., Horwitz, E., Lawton, C., Rosenthal, S., Sandler, H. and Shipley, W.: Phase III Trial of Long-Term Adjuvant Androgen Deprivation After Neoadjuvant Hormonal Cytoreduction and Radiotherapy in Locally Advanced Carcinoma of the Prostate: The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol, 21 (21):3972-3978, 2003. |
9202 |
gu/prostate
gleason
horm |
|
| gu/prostate |
Valicenti, R., Winter, K., Cox, J., Sandler, H., Bosch, W., Vijayakumar, S., Michalski, J. and Purdy, J.: RTOG 94-06: Is the Addition of Neoadjuvant Hormonal Therapy to Dose-Escalated 3D Conformal Radiation Therapy for Prostate Cancer Associated with Treatment Toxicity. Int J Radiat Onco Biol Phys, 57 (3):614-620, 2003. |
9406 |
gu/prostate
3D/horm |
|
| gu/prostate |
Pilepich, M., Winter, K., Lawton, C., Krisch, R., Wolkov, H., Movsas, B., Hug, E., Asbell, S. and Grignon, D.: Androgen Suppression Adjuvant to Radiotherapy in Carcinoma of the Prostate. Long-Term Results of Phase III RTOG Study 85-31. Proc Am Soc Thera Rad Oncol (ASTRO), Salt Lake City, UT, Int J Radiat Oncol Biol Phys, [57] (2) pg. S172-173, Abs. #82, 2003. |
8531 |
gu/prostate
horm |
|
| gu/prostate |
Chakravarti, A., Heydon, K., Wu, C.-L., Hammond, E., Pollack, A., Roach III, M., Wolkov, H., Okunieff, P., Komaki, R., Fontanesi, J., Abrams, R., Pilepich, M. and Shipley, W.: Loss of p16 Expression Is of Prognostic Significance in Locally Advanced Prostate Cancer: An Analysis From the Radiation Therapy Oncology Group Protocol 86-10. J Clin Oncol, 21 (17):3328-3334, 2003. |
8610 |
gu/prostate
markers/p16
horm |
|
| gu/prostate |
Michalski, J., Winter, K., Purdy, J., Wilder, R., Perez, C., Roach III, M., Parliament, M., Pollack, A., Markoe, A., Harms Sr, W. B., Sandler, H. and Cox, J.: Preliminary Evaluation of Low Grade Toxicity with Conformal Radiation Therapy for Prostate Cancer on RTOG 94-06 Dose Levels I & II. Int J Radiat Onco Biol Phys, 56 (1):192-198, 2003. |
9406 |
gu/prostate
3D |
|
| gu/bladder |
Shipley, W., Kaufman, D., Tester, W., Pilepich, M. and Sandler, H.: Overview of Bladder Cancer Trials in the Radiation Therapy Oncology Group. Perspectives in Bladder Cancer: Suppl to Cancer, 97 (8):2115-2119, 2003. |
multi |
gu/bladder
chemo/rt |
|
| gu/prostate |
Milanes-Yearsley, M., Hammond, E., Pajak, T., Cooper, J., Chang, C., Griffin, T., Nelson, D., Laramore, G. and Pilepich, M.: Tissue Micro-Array: A Cost and Time-Effective Method for Correlative Studies by Regional and National Cancer Study Groups. Mod Pathol, Dec.15 (12):1366-1373, 2002. |
|
gu/prostate
path |
|
| gu/prostate |
Pollack, A., Grignon, D., Heydon, K., Hammond, E., Lawton, C., Mesic, J., Fu, K., Porter, A., Abrams, R. and Shipley, W.: Prostate Cancer DNA Ploidy and Response to Salvage Hormone Therapy after Radiotherapy With or Without Short-Term Total Androgen Blockade: An Analysis of RTOG 86-10. J Clin Oncol, 21 (7):1238-1248, 2003. |
8610 |
path
DNA |
|
| gu/prostate |
Roach, M., Lu, J., Pilepich, M., Asbell, S., Mohiuddin, M. and Grignon, D.: Race and Survival of Men Treated for Prostate Cancer on Radiation Therapy Oncology Group Phase III Randomized Trials. J of Urology, 169 (1):245-250, 2003. |
7506, 7706, 8531, 8610 |
gu/prostate
horm |
|
| gu/prostate |
Roach, M., DeSilvio, M., Lawton, C., Uhl, V., Machtay, M., Seider, M., Rotman, M., Jones, C., Asbell, S., Valicenti, R., Han, S., Thomas, C. and Shipley, W.: Phase III Trial Comparing Whole-Pelvic Versus Prostate-Only Radiotherapy and Neoadjuvant Versus Adjuvant Combined Androgen Suppression: Radiation Therapy Oncology Group 94-13. J Clin Oncol, 21 (10):1904-1911, 2003. |
9413 |
gu/prostate
horm/rt |
|
| gu/prostate |
Sandler, H., Pajak, T., Hanks, G., Porter, A., DeSilvio, M. and Shipley, W.: Can Biochemical Failure (ASTRO Definition) Be Used as a Surrogate Endpoint for Prostate Cancer Survival in Phase III Localized Prostate Cancer Clinical Trials? Analysis of RTOG Protocol 92-02. Proceeding from Am Soc Clin Oncol (ASCO), Chicago, IL, J Clin Oncol, [22] (May 31-June 3, 2003) pg. 381, Abs. #1529, 2003. |
9202 |
gu/prostate
gleason
horm |
|
| gu/prostate |
Pilepich, M., Winter, K., Lawton, C., Krisch, R., Wolkov, H., Movsas, B., Hug, E., Asbell, S. and Grignon, D.: Phase III Trial of Androgen Suppression Adjuvant to Definitive Radiotherapy. Long Term Results of RTOG Study 85-31. Proceeding from Am Soc Clin Oncol (ASCO), Chicago, IL, J Clin Oncol, [22] (May 31-June 3, 2003) pg. 381, Abs. #1530, 2003. |
8531 |
gu/prostate
horm |
|
| gu/prostate |
Michalski, J., Winter, K., Perez, C., Purdy, J., Ryu, J., Parliament, M., Valicenti, R., Roach III, M., Sandler, H., Markoe, A. and Cox, J.: Toxicity Following 3D Radiation Therapy For Prostate Cancer On RTOG 94-06 Dose Level IV. RSNA, Chicago, IL, RSNA Meeting Booklet, pg. 32, Abs. #Invited, P., 2002. |
9406 |
3D |
|
| gu/prostate |
Michalski, J., Winter, K., Purdy, J., Wilder, R., Perez, C., Roach III, M., Parliament, M., Pollack, A., Markoe, A., Harms Sr, W. B., Sandler, H. and Cox, J.: Grade 2 Toxicity on RTOG 94-06: Robbing Peter to Pay Paul? Amer Assoc of Physicists in Med, 12 48-54, 2001. |
9406 |
3D |
|
| gu/prostate |
Shipley, W., Lu, J., Pilepich, M., Heydon, K., Roach, M., Wolkov, H., Sause, W., Rubin, P., Lawton, C. and Machtay, M.: Effect of a Short Course of Neoadjuvant Hormonal Therapy on the Response to Subsequent Androgen Suppression in Prostate Cancer Patients with Relapse after Radiotherapy: A Secondary Analysis of the Randomized Protocol RTOG 86-10. Int J Radiat Onco Biol Phys, 54 (5):1302-1310, 2002. |
8610 |
horm |
|
| gu/prostate |
Michalski, J., Winter, K., Purdy, J., Wilder, R., Perez, C., Roach III, M., Parliament, M., Pollack, A., Markoe, A., Harms Sr, W. B., Sandler, H. and Cox, J.: Trade-Off to Low Grade Toxicity with Conformal Radiation Therapy for Prostate Cancer on RTOG 94-06. Sem in Rad Oncol, 12 (1 (Suppl 1)):75-80, 2002. |
9406 |
3D |
|
| gu/prostate |
Chakravarti, A., Heydon, K., Lee, C., Hammond, E., Pollack, A., Roach III, M., Wolkov, H., Okunieff, P., Komaki, R., Fontanesi, J., Abrams, R., Pilepich, M. and Shipley, W.: Loss of p16 expression is of Prognostic Significance in Locally Advanced Prostate Cancer: All Analysis from RTOG 86-10. Amer Urology Assoc (AUA), Orlando, FL, J of Urology, pg. Abs. #101588, 2002. |
8610 |
markers/p16 horm |
|
| gu/prostate |
Lee, W. R., Scott, C., Lawton, C., Morton, G., Pisansky, T., Baikadi, M., Bruner, D. and Sandler, H.: Health-Related Quality of Life (HRQOL) in Men Treated with Prostate Brachytherapy Alone on Radiation Therapy Oncology Group (RTOG) Trial 98-05. Proc of Am Soc Ther Rad Oncol (ASTRO), New Orleans. LA, Int J Radiat Oncol Biol Phys, [54] (2) pg. 47-48, Abs. #77, 2002. |
9805 |
QOL |
|
| gu/prostate |
Ryu, J., Winter, K., Michalski, J., Purdy, J., Markoe, A., Earle, J., Perez, C., Roach III, M., Sandler, H., Pollack, A. and Cox, J.: Interim Report of Toxicity from 3D Conformal Radiation Therapy (3D-CRT) for Prostate Cancer on 3DOG/RTOG 94-06, Level III (79.2 Gy). Int J Radiat Onco Biol Phys, 54 (4):1036-1046, 2002. |
9406 |
3D |
|
| gu/prostate |
Valicenti, R., Winter, K., Cox, J., Sandler, H. and Michalski, J.: The Effect On Toxicity Of Induction Hormonal Therapy In Prostate Cancer Patients Receiving Dose Escalated 3D Conformal Radiation Therapy On RTOG 94-06. Proc Am Soc Thera Rad Oncol (ASTRO), New Orleans, LA, Int J Radiat Oncol Biol Phys, [54] (2) pg. 133-134, Abs. #226, 2002. |
9406 |
3D/horm |
|
| gu/prostate |
Michalski, J., Winter, K., Perez, C., Purdy, J., Ryu, J., Parliament, M., Valicenti, R., Roach III, M., Sandler, H., Markoe, A. and Cox, J.: Toxicity Following 3D Radiation Therapy For Prostate Cancer On RTOG 94-06 Dose Level IV. Proc Am Soc Thera Rad Oncol (ASTRO), New Orleans, LA, Int J Radiat Oncol Biol Phys, [54] (2) pg. 107, Abs. #181, 2002. |
9406 |
3D |
|
| gu/prostate |
Hughes, L., Heydon, K., Edmonds, P., Hammond, E. and Dicker, A.: Cyclooxygenase 2 (COX-2) Expression in Locally Advanced Prostate Cancer: Secondary Analysis of Radiation Therapy Oncology Group (RTOG) 86-10. Proc Am Soc Thera Rad Oncol (ASTRO), New Orleans, LA, Int J Radiat Oncol Biol Phys, [54] (2) pg. 271-272, Abs. #2102, 2002. |
8610 |
path |
|
| gu/prostate |
Roach, M., DeSilvio, M., Lawton, C., Uhl, V., Machtay, M., Seider, M., Rotman, M., Jones, C., Asbell, S., Valicenti, R., Han, S., Thomas, C. and Shipley, W.: Neoadjuvant Hormonal Therapy (NHT) With Whole-Pelvic (WP) Radiotherapy (RT) Improves Progression-Free Survival (PFS): RTOG (Radiation Therapy Oncology Group) 9413, A Phase III Randomized Trial. Amer Urology Assoc (AUA), Orlando, FL, J of Urology, pg. Abs. #500164, 2002. |
9413 |
horm/rt |
|
| gu/bladder |
Tester, W., Caplan, R., Heaney, J., Venner, P., Whittington, R., Byhardt, R., True, L. and Shipley, W.: Neoadjuvant Combined Modality Program With Selective Organ Preservation For Invasive Bladder Cancer: Results of Radiation Therapy Oncology Group Phase II Trial 88-02. J Clin Oncol: Classic Papers & Current Comments, 6 (2):379-387, 2001. |
8802 |
chemo/surg |
|
| gu/bladder |
Chakravarti, A., Winter, K., Wu, C.-L., Kaufman, D., Hammond, E., Parliament, M., Tester, W., Hagan, M., Grignon, D., Heney, N., Sandler, H. and Shipley, W.: Expression of The Epidermal Growth Factor Receptor (EGFR) Is Associated with Improved Outcome In Muscle-Invading Bladder Cancer. Proceeding from Am Soc Clin Oncol (ASCO), Orlando, FL, J Clin Oncol, 21: pg. 179a, Abs. #713, 2002. |
8802, 8903, 9506, 9706 |
markers/p16/pRB horm |
|
| gu/prostate |
Movsas, B., Chapman, J., Hanlon, A., Horwitz, E., Pinover, W., Greenberg, R., Stobbe, C. and Hanks, G.: Hypoxia in Human Prostate Carcinoma. Am J Clin Oncol (CCT), 24 (5):458-461, 2001.
Ahmed, M., Chendil, D., Lele, S., Venkatasubbarao, K., Dey, S., Ritter, M., Rowland, R. and Mohiuddin, M.: Early Growth Response-1 Gene: Potential Radiation Response Gene Marker in Prostate Cancer. Am J Clin Oncol (CCT), 24 (5):500-505, 2001.
Roach, M., DeSilvio, M., Lawton, C., Uhl, V., Machtay, M., Seider, M., Rotman, M., Jones, C., Asbell, S., Valicenti, R., Han, S., Thomas, C. and Shipley, W.: Neoadjuvant Hormonal Therapy (NHT) with Whole-Pelvic (WP) Radiotherapy (RT) Improves Progression-Free Survival (PFS): RTOG (Radiation Therapy Oncology Group) 9413, a Phase III Randomized Trial. Proceeding from Am Soc Clin Oncol (ASCO), Orlando, FL, J Clin Oncol, 21: pg. "The Best of Oncology Session", Abs. #711, 2002. |
9413 |
horm/rt |
|
| gu/bladder |
Hagan, M., Winter, K., Kaufman, D., Shipley, W., Heney, N., Toonkel, L., Jones, C. and Roberts, J.: RTOG 97-06: Initial Report Of A Phase I/II Trial of Bladder-Conservation Employing TURB, Accelerated Irradiation Sensitized With Cisplatin Followed By Adjuvant MCV Chemotherapy. Proc of Am Soc Ther Rad Oncol (ASTRO), San Francisco, CA, Int J Radiat Oncol Biol Phys, 51(3, Suppl 1): pg. 14, Abs. #20, 2001. |
9706 |
rt/chemo |
|
| gu/prostate |
Jimenez, R., Lu, J., Mesic, J., Roach, M., Pilepich, M., Sause, W., Brassachio, R., Lawton, C. and Grignon, D.: Mitotic Figures as a Prognostic Marker in Prostate Cancer (PCa) Patients Treated with Radiation Therapy: A Radiation Therapy Oncology Group (RTOG) Study. US/Canadian Pathology, Atlanta, GA, J US & Canadian Acad Path, pg. 112A, Abs. #647, 2001. |
8610 |
horm/path |
|
| gu/prostate |
Ryu, J., Winter, K., Michalski, J., Purdy, J., Markoe, A., Earle, J., Perez, C., Roach III, M., Sandler, H., Cox, J. and Pollack, A.: Preliminary Report of Toxicity Following 3D Conformal Radiation Therapy (3DCRT) For Prostate Cancer on 3DOG/RTOG 9406, Level III (79.2 Gy). Proc of Am Soc Ther Rad Oncol (ASTRO), San Francisco, CA, Int J Radiat Oncol Biol Phys, 51(3, Suppl 1): pg. 136-137, Abs. #244, 2001. |
9406 |
3D |
|
| gu/prostate |
Roach, M., Lu, J., Lawton, C., Hsu, I.-C., Machtay, M., Seider, M., Rotman, M., Jones, C., Asbell, S., Valicenti, R., Han, S., Thomas, C. and Shipley, W.: A Phase III Trial Comparing Whole-Pelvic (WP) versus Prostate Only (PO) Radiotherapy and Neoadjuvant versus Adjuvant Total Androgen Suppression (TAS): Preliminary Analysis of Radiation Therapy Oncology Group (RTOG) 94-13. Proc of Am Soc Ther Rad Oncol (ASTRO), San Francisco, CA, Int J Radiat Oncol Biol Phys, 51(3, Suppl 1): pg. 3, Abs. #P5, 2001. |
9413 |
horm/rt |
|
| gu/bladder |
Kaufman, D., Winter, K., Shipley, W., Heney, N., Chetner, M., Souhami, L., Zlotecki, R., Sause, W. and True, L.: The Initial Results in Muscle-Invading Bladder Cancer of RTOG 95-06: Phase I/II Trial of Transurethral Surgery Plus Radiation Therapy with Concurrent Cisplatin and 5-Fluorouracil Followed by Selective Bladder Preservation or Cystectomy Depending on the Initial Response. The Oncologist, 5(6):471-476, 2000. |
9506 |
rt/chemo |
|
| gu/prostate |
Pilepich, M., Winter, K., Fu, K., Russell, A., Sause, W., Rubin, P., Lawton, C., Machtay, M. and Grignon, D.: Phase III Radiation Therapy Oncology Group (RTOG) Trial 86-10 of Androgen Deprivation Adjuvant to Definitive Radiotherapy in Locally Advanced Carcinoma of the Prostate. Int J Radiat Onco Biol Phys, 50(5):1243-1252, 2001. |
|
horm |
|
| gu/prostate |
Gillin, M., Dunning, B., Lawton, C., Byhardt, R., Morton, G., Brereton, H., Pisansky, T., Wasserman, T. and Lopez, F.: Initial Physics Review of the RTOG 98-05 Prostate Brachytherapy Protocol. Am Assoc of Phys in Med (AAPM), Salt Lake City, UT, Medical Physics, 28 (6) #WE-C-BRA-06, 1280, 2001. |
9805 |
physics/brachy/QA/IGRT |
|
| gu/prostate |
Horwitz, E., Winter, K., Hanks, G., Lawton, C., Russell, A. and Machtay, M.: Subset Analysis of RTOG 85-31 and 86-10 Indicates an Advantage for Long-Term Versus Short-Term Adjuvant Hormones for Patients with Locally Advanced Non-Metastatic Prostate Cancer Treated with Radiation Therapy. Int J Radiat Onco Biol Phys, 49(4):947-956, 2001. |
8531, 8610 |
horm |
|
| gu/prostate |
Lawton, C., Winter, K., Murray, K., Machtay, M., Mesic, J., Hanks, G., Coughlin, C. and Pilepich, M.: Updated Results of the Phase III Radiation Therapy Oncology Group (RTOG) Trial 85-31 Evaluating the Potential Benefit of Androgen Suppression Following Standard Radiation Therapy for Unfavorable Prognosis Carcinoma of the Prostate. Int J Radiat Oncol Biol Phys, 49(4):937-946, 2001. |
8531 |
horm |
|
| gu/prostate |
Milanes-Yearsley, M., Hammond, E. and Pajak T.: Tissue Micro Arrays in Immuno-Histochemistry: A Practical, Cost-Effective and Time-Effective Research Tool. US/Canadian Pathology, Atlanta, GA, J US & Canadian Acad Path, #1382, 234A, 2001. |
|
path |
|
| gu/prostate |
Jimenez, R., Lu, J., Mesic, J., Roach, M., Pilepich, M., Sause, W., Brassachio, R., Lawton, C. and Grignon, D.: Mitotic Figures as a Prognostic Marker in Prostate Cancer (PCa) Patients Treated with Radiation Therapy: A Radiation Therapy Oncology Group (RTOG) Study. US/Canadian Pathology, Atlanta, GA, J US & Canadian Acad Path, #647, 112A, 2001./FONT> |
8610 |
horm/path |
|
| gu/prostate |
Ryu, J., Winter, K., Michalski, J., Purdy, J., Markoe, A., Earle, J., Perez, C., Roach III, M., Sandler, H., Pollack, A. and Cox, J.: Interim Report of Toxicity from 3D Conformal Radiation Therapy (3DCRT) for Prostate Cancer on 3DOG/RTOG 9406, Level III (79.2 GY). Proceeding from Am Soc Clin Oncol (ASCO), San Francisco, CA, J Clin Oncol, 20 #725, 182a, 2001. |
9406 |
3D |
|
| gu/prostate |
Shipley, W., Heydon, K., Pilepich, M., Roach III, M., Machtay, M., Mesic, J., Sause, W., Rubin, P. and Lawton, C.: A Secondary Analysis of RTOG 86-10: Does the Extent of Progression at the Time of Initiating Salvage Hormone Therapy Influence Survival in Patients with Prostate Cancer Who Failed Initial Treatment with Irradiation? Proc Am Soc Clin Oncol (ASCO), San Francisco, CA, J Clin Oncol, 20 #726, 182a, 2001. |
8610 |
horm |
|
| gu/prostate |
Hanks, G., Lu, J., Machtay, M., Venkatesan, V., Pinover, W., Byhardt, R. and Rosenthal, S.: RTOG Protocol 92-02: A Phase III Trial of the use of Long Term Total Androgen Suppression Following Neoadjuvant Hormonal Cytoreduction and Radiotherapy in Locally Advanced Carcinoma of the Prostate. Proc of Am Soc Ther Rad Oncol (ASTRO), Boston, MA, Int J Radiat Oncol Biol Phys, [48], pg. 112, Abs. #4, 2000. |
9202 |
horm |
|
| gu/prostate |
Dalesio, O., van Tinteren, H., Peto, R., Clarke, M. and Schroder, F.: Androgen Blockade in Prostate Cancer [Correspondence]. The Lancet, 356(July):341-342, 2000. |
|
stat |
|
| gu/prostate |
Bostwick, D., Grignon, D., Hammond, E., Amin, M., Cohen, M., Crawford, D., Gospadarowicz, M., Kaplan, R., Miller, D., Montironi, R., Pajak, T., Pollack, A., Srigley, J. and Yarbro, J.: Prognostic Factors in Prostate Cancer: College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med, 124(July):995-1000, 2000. |
|
path |
|
| gu/prostate |
Anderson, P., Winter, K., Hanks, G., Grignon, D. and Pilepich, M.: Gleason Score 4+3 Prostate Cancer Patients Have Worse bNED Outcome Compared to Gleason Score 3+4 Treated with Radiation Therapy Alone: Subset Analysis of RTOG 85-31 and 86-10. Proc of Am Soc Ther Rad Oncol (ASTRO), Boston, MA, Int J Radiat Oncol Biol Phys, [48], pg. 205-206, Abs. #187, 2000. |
8531, 8610 |
path |
|
| gu/prostate |
Lu, J.: Statistical Aspects of Evaluating Treatment and Prognostic Factors for Clinically Localized Prostate Cancer. Seminars in Urologic Oncology, 18(2):83-92, 2000. |
|
stat |
|
| gu/prostate |
Lu, J. and Pajak, T.: Statistical Power for a Long-Term Survival Trial with a Time-Dependent Treatment Effect. Control Clin Trials, 21(6):561-573, 2000. |
8531 |
stat |
|
| gu/prostate |
Michalski, J., Winter, K., Purdy, J., Wilder, R., Perez, C., Roach, M., Parliament, M., Pollack, A., Markoe, A., Harms, W., Sandler, H. and Cox, J.: Update of Toxicity Following 3D Radiation Therapy for Prostate Cancer on RTOG 94-06. Proc of Am Soc Ther Rad Oncol (ASTRO), Boston, MA, Int J Radiat Oncol Biol Phys, [48], pg. 228, Abs. #233, 2000. |
9406 |
3D |
|
| gu/prostate |
Pajak, T., Clark, G., Sargent, D., McShane, L. and Hammond, E.: Statistical Issues in Tumor Marker Studies. Arch Path & Lab Med, 124(1011-1015, 2000. |
8610 |
stat |
|
| gu/prostate |
Pilepich, M., Winter, K., Byhardt, R., Mesic, J., Machtay, M., Hanks, G., Roach, M. and Sause, W.: Androgen Ablation Adjuvant to Defintive Radiotherapy in Carcinoma of the Prostate: Year 2000 Update of RTOG Phase III Studies 86-10 and 85-31. Proc of Am Soc Ther Rad Oncol (ASTRO), Boston, MA, Int J Radiat Oncol Biol Phys, [48], pg. 169, Abs. #114, 2000. |
8531, 8610 |
horm |
|
| gu/prostate |
Roach, M., Lu, J., Pilepich, M., Asbell, S. O., Mohuidden, M., Terry, R. and Grignon, D.: Race is Not an Independent Predictor of Disease Specific Long Term Survival Among Men Treated for Prostate Cancer on Radiation Therapy Oncology Group (RTOG) Trials. Amer Urology Assoc (AUA), Atlanta, GA, pg. Abs. 2000. |
7506, 7706, 8531, 8610 |
horm |
|
| gu/prostate |
Roach, M., Lu, J., Pilepich, M., Asbell, S., Mohuidden, M., Terry, R., Grignon, D., Lawton, C., Shipley, W. and Cox, J.: Predicting Long Term Survival, and the Need for Hormonal Therapy: A Meta-Analysis of RTOG Prostate Cancer Trials. Int J Radiat Oncol Biol Phys, 47(3):617-627, 2000. |
7706, 7506, 8531, 8610 |
stat |
|
| gu/prostate |
Roach, M., Lu, J., Pilepich, M., Asbell, S., Mohuidden, M., Terry, R. and Grignon, D.: Four Prognostic Subgroups Predict Long Term Survival from Prostate Cancer Following Radiotherapy Alone on Radiation Therapy Oncology Group Clinical Trials. Int J Radiat Oncol Biol Phys, 47(3):609-615, 2000. |
7706, 7506, 8531, 8610 |
other (rt) |
|
| gu/prostate |
Lin, X.: Mean Dose of Radiation to the Bulb of the Penis Correlates with Risk of Impotence at 24 Months: Preliminary Analysis of Radiation Therapy Oncology Group (RTOG) Phase I / II Dose Escalation Trial 94-06. Proc of Am Soc Ther Rad Oncol (ASTRO), Boston, MA, Int J Radiat Oncol Biol Phys, [48], pg. 316, Abs. #2194, 2000. |
9406 |
3D |
|
| gu/prostate |
Scott, C., Stern, J., Asbell, S., Brereton, D., Peer, J., Littman, P., Scarantino, C. and Bruner, D.: Quality of Life of Long-Term Survivors of Head and Neck or Prostate Cancer: Preliminary Results from a Survey of Survivors from Radiation Therapy Oncology Group (RTOG) Clinical Trials. Proceeding from Int Soc Qual of Life Research (ISOQOL), Vancouver, Canada, Quality of Life Research, pg. Abs. 2000. |
|
QOL |
|
| gu/prostate |
Shipley, W., Lu, J., Pilepich, M., Roach, M., Russell, A., Sause, W., Rubin, P., Byhardt, R. and Machtay, M.: NeoAdjuvant Hormone Treatment Does Not Compromise the Benefits of Subsequent Androgen Suppression with Patients in Prostate Cancer who Fail Initial Radiation Therapy: A Secondary Analysis of the RTOG Phase III Trial 86-10. Proc of Am Soc Ther Rad Oncol (ASTRO), Boston, MA, Int J Radiat Oncol Biol Phys, [48], pg. 169-170, Abs. #115, 2000. |
8610 |
horm |
|
| gu/prostate |
Valicenti, R., Lu, J., Pilepich, M., Asbell, S. and Grignon, D.: Survival Advantage From Higher-Dose Radiation Therapy For Clinically Localized Prostate Cancer Treated On The Radiation Therapy Oncology Group Trials. J Clin Oncol, 18(14):2740-2746, 2000. |
7506, 7706, 8531, 8610 |
rad/dose |
|
| gu/prostate |
Lu, J.: The Design of Survival Clinical Trial with an Intermediate Event. Society for Clinical Trials, Toronto, Canada, Controlled Clin Trials, [21], pg. 49S, Abs. #13, 2000. |
|
stat |
|
| gu/prostate |
Hanks, G., Lu, J., Machtay, M., Venkatesan, V., Pinover, W., Byhardt, R. and Rosenthal, S.: RTOG Protocol 92-02: A Phase III Trial of the Use of Long Term Total Androgen Suppression Following Neoadjuvant Hormonal Cytoreduction and Radiotherapy in Locally Advanced Carcinoma of the Prostate. Proc of Am Soc Clin Oncol (ASCO), New Orleans, LA, J Clin Oncol, [19], pg. 327a, Abs. #1284, 2000. |
9202 |
horm |
|
| gu/prostate |
Michalski, J. M., Purdy, J. A., Winter, K., Roach, M., Vijayakumar, S., Sandler, H. M., Markoe, A. M., Ritter, M. A., Russell, K. J., Sailer, S., Harms, W. B., Perez, C. A., Wilder, R. B., Hanks, G. E. and Cox, J. D.: Preliminary Report of Toxicity Following 3D Radiation Therapy For Prostate Cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys, 46(2):391-402, 2000. |
9406 |
3D |
|
| gu/prostate |
Jiminez, R., Lu, J., Russell, A., Fu, K., Pilepich, M., Sause, W., Okunieff, P., Byhardt, R. and Grignon, D.: Perineural Invasion as a Prognostic Marker in Patients Treated by Radiation Therapy (RT): A Radiation Therapy Oncology Group (RTOG) Study. US/Canadian Pathology, New Orleans, LA, J US & Canadian Acad Path, [13], pg. 113A, Abs. #653, 2000. |
8610 |
horm/path |
|
| gu/prostate |
(PCTCG), P. C. T. C. G.: Maximum Androgen Blockade in Advanced Prostate Cancer: An Overview of the Randomised Trials. Prostate Cancer Trialists' Collaborative Group. The Lancet, 355(9214):1491-1498, 2000. (RTOG/Meta Analysis) |
9509 |
stat |
|
| gu/bladder |
Shipley, W., Winter, K., Kaufman, D., Heney, N., Chetner, M., Souhami, L., Zlotecki, R. and Sause, W.: Initial Results of RTOG 95-06: A Phase I/II Trial of Transurethral Surgery and Fractionated Twice-Daily Radiation with Concurrent Cisplatin and 5-Fluorouracil Followed Either by Selective Bladder Preservation or Cystectomy for Patients with Muscle-Invading Bladder Cancer. Proc Am Soc Thera Rad Oncol (ASTRO), San Antonio, TX, Int J Radiat Oncol Biol Phys, [45], pg. 222, Abs. #145, 1999. |
9506 |
rt/chemo |
|
| gu/prostate |
Corn, B., Winter, K. and Pilepich, M.: Does Androgen Suppression Enhance the Efficacy of Postoperative Irradiation? A Secondary Analysis Of RTOG 85-31. Radiation Therapy Oncology Group. Urology, 54(3):495-502, 1999. |
8531 |
horm |
|
| gu/prostate |
Hammond, E. H., Grignon, D. J., Lu, J., Pilepich, M., Russell, A. H. and Fu, K. K.: Multiple Tumor Marker Analysis in a Prostate Clinical Trial Population: RTOG 86-10. Amer Urology Assoc, Dallas, Texas, pg. Abs. 1999. |
8610 |
horm/path |
|
| gu/prostate |
Horwitz, E., Winter, K., Hanks, G., Byhardt, R., Russell, A., Machtay, M. and Pilepich, M.: Long-Term Outcome For Patients With Locally Advanced Non-Metastatic Prostate Cancer Treated With Adjuvant Hormones And Radiation Therapy Versus Radiation Therapy Alone: Subset Analysis of RTOG 85-31 and 86-10. Proc Am Soc Thera Rad Oncol (ASTRO), San Antonio, TX, Int J Radiat Oncol Biol Phys, [45], pg. 220-221, Abs. #142, 1999. |
8531,8610 |
horm |
|
| gu/prostate |
Scott, C., Roach, M., Lawton, C., Gallagher, M., Doggett, S., Hanks, G., Coughlin, C. and Pilepich, M.: Q-Twist Analysis For Prostate Cancer Treated With Radiation Therapy With Or Without Hormonal Therapy: RTOG 86-10. Proceeding from Int Soc Qual of Life Research (ISOQOL), Quality of Life Research, [8], pg. 568, Abs. #48, 1999. |
8610 |
QOL |
|
| gu/prostate |
Lawton, C., Winter, K., Murray, K., Machtay, M., Mesic, J., Hanks, G., Coughlin, C. and Pilepich, M.: Updated Results of the Phase III radiation Therapy Oncology Group (RTOG) Trial 85-31 Evaluating the Potential Benefit of Androgen Deprivation Following Standard Radiation Therapy for Unfavorable Prognosis Carcinoma of the Prostate. Proc of Am Soc Clin Oncol (ASCO), Atlanta, GA, J Clin Oncol, [18], pg. 311a, Abs. #1195, 1999. |
8531 |
horm |
|
| gu/prostate |
Hammond, E. H., Grignon, D. J., Lu, J., Pilepich, M., Russell, A. H. and Fu, K. K.: Multiple Tumor Marker Analysis in a Prostate Clinical Trial Population: RTOG 86-10. Amer Urology Assoc, Dallas, Texas, pg. Abs. 1999. |
8610 |
horm/path |
|
| gu/prostate |
Valicenti, R. K., Lu, J., Grignon, D., Terry, R., Pilepich, M. and Asbell, S.: Radiation Dose-Response is Gleason Score Dependent on the Radiation Therapy Oncology Group Prostate Cancer Trials. Proc of Am Soc Clin Oncol (ASCO), Atlanta, GA, J Clin Oncol, [18], pg. 311a, Abs. #1194, 1999. |
7506, 7706, 8531, 8610 |
rad/dose |
|
| gu/prostate |
Roach, M., Lu, J., Pilepich, M., Asbell, S. O., Mohuidden, M., Terry, R. and Grignon, D.: Long Term Survival After Radiotherapy Alone: Radiation Therapy Oncology Group Prostate Cancer Trials. J of Urology, 161(3):864-868, 1999. |
7706, 7506, 8531, 8610 |
other (rt) |
|
| gu/bladder |
Shipley, W., Winter, K., Kaufman, D., Lee, W., Heney, N., Tester, W., Donnelly, B., Venner, P., Perez, C., Murray, C., Doggett, R. and True, L.: Phase III Trial of Neoadjuvant Chemotherapy in Patients with Invasive Bladder Cancer Treated with Selective Bladder Preservation by Combined Radiation Therapy and Chemotherapy: Initial Results of RTOG 89-03. J Clin Oncol, 16(1):3576-3583, 1998. |
|
chemo |
|
| gu/prostate |
Bruner, D., Scott, C., McGowan, D., Lawton, C., Hanks, G., Prestidge, B., Gaspar, L., Gore, E. and Asbell, S.: Validation of the Sexual Adjustment Questionnaire (SAQ) in Prostate Cancer Patients Enrolled On Radiation Therapy Oncology Group (RTOG) Studies 90-20 and 94-08. Proc Am Soc Thera Rad Oncol (ASTRO), Phoenix, AZ, Int J Radiat Oncol Biol Phys, [42], pg. 202, Abs. #156, 1998. |
|
QOL |
|
| gu/prostate |
Pilepich, M., Winter, K., Fu, K., Russell, A., Sause, W., Rubin, P., Byhardt, R., Machtay, M. and Grignon, D.: Phase III Radiation Therapy Oncology Group (RTOG) Trial 86-10 of Androgen Deprivation Before and During Radiotherapy in Locally Advanced Carcinoma of the Prostate. Proc Am Soc Thera Rad Oncol (ASTRO), Phoenix, AZ, Int J Radiat Oncol Biol Phys, [42], pg. 177, Abs. #105, 1998. |
|
horm |
|
| gu/prostate |
Michalski, J., Purdy, J., Winter, K., Roach, M., Vijayakumar, S., Sandler, H., Markoe, A., Ritter, M., Russell, K., Sailer, S., Harms, W., Perez, C., Hanks, G. and Cox, J.: Preliminary Report of Toxicity Following 3D Radiation Therapy for Prostate Cancer on 3DOG/RTOG 9406. Proc Am Soc Thera Rad Oncol (ASTRO), Phoenix, AZ, Int J Radiat Oncol Biol Phys, [42], pg. 142, Abs. #35, 1998. |
|
3D |
|
| gu/prostate |
Roach, M., Lu, J., Pilepich, M., Asbell, S., Mohuidden, M., Terry, R., Grignon, D., Lawton, C. and Shipley, W.: Predicting Survival, and the Role of Androgen Suppressive Therapy (AST): Radiation Therapy Oncology Group RTOG Phase III Randomized Prostate Cancer Trials. Proc Am Soc Thera Rad Oncol (ASTRO), Phoenix, AZ, Int J Radiat Oncol Biol Phys, [42], pg. 177, Abs. #106, 1998. |
|
horm |
|
| gu/prostate |
Bruner, D., Scott, C., McGowan, D., Lawton, C., Hanks, G., Prestidge, B., Han, S., Gore, E., Asbell, S. and Rotman, M.: Factors Influencing Sexual Outcomes in Prostate Cancer (PC) Patients Enrolled on Radiation Therapy Oncology Group (RTOG) Studies 90-20 and 94-08. Proceeding from Int Soc Qual of Life Research (ISOQOL), Baltimore, MD, Quality of Life Research, [7], pg. 575, Abs. 1998. |
|
QOL |
|
| gu/prostate |
Hammond, E., Lu, J., Doggett, R., Fu, K., BenJosef, E., Sause, W., Grignon, D., Byhardt, R., Abrams, R., Brasacchio, R., Zhou, R. and Mesic, J.: Microvessel Density in Prostatic Biopsies in a Phase III Trial (RTOG 86-10). US/Canadian Pathology, Boston, MA, Laboratory Invest/Modern Path, pg. Abs. 1998. |
|
horm/path |
|
| gu/prostate |
Cox, J., Lu, J., Pilepich, M., Asbell, S. and Mohuidden, M.: Does Hormone Therapy Influence the Risk of Late Effects in Normal Tissues Irradiated for Carcinoma of the Prostate?: Data From Prospective Trials of the Radiation Therapy Oncology Group (RTOG). Am Radium Society (ARS), Monte Carlo, Monaco, pg. Abs. 1998. |
|
horm/lateff |
|
| gu/prostate |
Roach, M., Lu, J., Pilepich, M., Asbell, S. O., Mohuidden, M., Terry, R. and Grignon, D.: Long Term Survival in 1500 Men Treated for Prostate Cancer with Radiotherapy Alone (XRT): Based on Radiation Therapy Oncology Group (RTOG) Protocols 7706, 7506, 8531 and 8610. Amer Urology Assoc (AUA), San Diego, CA, pg. Abs. 1998. |
|
other (rt) |
|
| gu/prostate |
Corn, B., Winter, K. and Pilepich, M.: Does Androgen Suppression Enhance The Efficacy of Post-Operative Irradiation: A Secondary Analysis of RTOG 85-31. Amer Urology Assoc (AUA), San Diego, CA, pg. Abs. 1998. |
|
horm |
|
| gu/bladder |
Shipley, W., Winter, K., Kaufman, D., Lee, W., Heney, N., Tester, W., Donnelly, B., Venner, P., Perez, C., Murray, C., Doggett, R. and True, L.: An RTOG Phase III Trial (#89-03) of Neoadjuvant Chemotherapy in Patients with Invasive Bladder Cancer Treated with Selective Bladder Preservation by Combined Radiation Therapy and Chemotherapy. Proc of Am Soc Clin Oncol (ASCO), Los Angeles, CA, J Clin Oncol, [17], pg. 311a, Abs. #1197, 1998. |
|
chemo |
|
| gu/prostate |
Hanks, G., Buzydlowski, J., Sause, W., Emami, B., Rubin, P., Parsons, J. A., Russell, A., Byhardt, R., Earle, J. and Pilepich, M.: Ten Year Outcomes for Pathologic Node Positive Patients Treated in RTOG 75-06. Int J Radiat Oncol Biol Phys, 40(4):765-768, 1998. |
|
other (radiation) |
|
| gu/prostate |
Asbell, S. O., Martz, K. L., Shin, K. H., Sause, W. T., Doggett, R. L., Perez, C. A. and Pilepich, M. V.: Impact of Surgical Staging in Evaluating the Radiotherapeutic Outcome in RTOG 77-06, A Phase III Study for T1BN0M0 (A2) and T2N0M0 (B) Prostate Carcinoma. Int J Radiat Oncol Biol Phys, 40(4):769-782, 1998. |
|
surg |
|
| gu/prostate |
Lu, J., Pajak, T. and Winter, K.: Statistical Power for a Long Term Survival Trial for an Elderly Population. Soc Clinical Trials, Atlanta, GA, Controlled Clin Trials, [19], pg. 77S-78S, Abs. #P02, 1998. |
|
stat |
|
| gu/prostate |
Roach, M., Lu, J., Pilepich, M., Asbell, S., Mohuiden, M., Terry, R. and Grignon, D.: Four Prognostic Subgroups Predict Survivals For Men Treated for Prostate Cancer with Radiotherapy Alone: Based on Radiation Therapy Oncology Group (RTOG) 7706, 7506, 8531 & 8610. Proc of Am Soc Clin Oncol (ASCO), Los Angeles, CA, J Clin Oncol, [17], pg. 312a, Abs. #1201, 1998. |
|
other (radiation) |
|
| gu/prostate |
Pilepich, M., Winter, K., Fu, K., Russell, A., Sause, W., Rubin, P., Byhardt, R., Machtay, M. and Grignon, D.: Phase III Radiation Therapy Oncology Group (RTOG) Trial of Androgen Depravation Before and During Radiotherapy in Locally Advanced Carcinoma of the Prostate. Proc of Am Soc Clin Oncol (ASCO), Los Angeles, CA, J Clin Oncol, [17], pg. 308a, Abs. #1185, 1998. |
|
horm |
|
| gu/bladder |
Shipley, W. U., Winter, K., Lee, R., Kaufman, D., Heney, N., Tester, W., Venner, P., Perez, C., Murray, K. and Doggett, R.: Initial Results of RTOG 89-03: A Phase III Trial of Neoadjuvant Chemotherapy in Patients with Invasive Bladder Cancer Treated with Selective Bladder Preservation by Combined Radiation Therapy and Chemotherapy. Proc Am Soc Thera Rad Oncol (ASTRO), Orlando, FL, In J Radiat Oncol Biol Phys, [39], pg. 155, Abs. #41, 1997. |
|
chemo |
|
| gu/prostate |
Grignon, D., Pajak, T., Winter, K., Pilepich, M., Byhardt, R., Lawton, C., Gallagher, M., Mesic, J., Roach, M., Hanks, G., Coughlin, C. and Porter, A.: Central Review vs. Institutional Gleason Grading and Its Impact on Phase III Clinical Trial Analysis: A Review of RTOG Protocol 85-31. United States and Canadian Acadamy of Pathology Meeting, Toronto, Canada, Modern Path, [10], pg. 77a, Abs. #436, 1997. |
|
path |
|
| gu/bladder |
Shipley, W. U.: RTOG Clinical Trials in Locally Advanced Prostate Cancer: Combined Androgen Suppression/Radiotherapy Improves Progression-Free Survival. First Sonoma Conf, Sonoma, CA, Onc News Internat'l, [6], pg. 19-20, Abs. 1997. |
|
horm |
|
| gu/bladder |
Vijayakumar, S., Winter, K., Sause, W., Gallagher, M., Michalski, J., Roach, M., Porter, A. and Bondy, M.: Prostate-Specific Antigen Levels are Higher in African-American Than in White Patients in a Multicenter Registration Study: Results of RTOG 94-12. Int J Radiat Oncol Biol Phys, 40(1):17-25, 1998. |
|
spec pop/epid |
|
| gu/bladder |
Shipley, W. U., Winter, K., Lee, R., Kaufman, D., Heney, N., Tester, W., Venner, P., Perez, C., Murray, K. and Doggett, R.: Initial Results of RTOG 89-03: A Phase III Trial of Neoadjuvant Chemotherapy in Patients with Invasive Bladder Cancer Treated with Selective Bladder Preservation by Combined Radiation Therapy and Chemotherapy. Proc Am Soc Thera Rad Oncol (ASTRO), Orlando, FL, In J Radiat Oncol Biol Phys, [39], pg. 155, Abs. #41, 1997. |
|
chemo |
|
| gu/prostate |
Lawton, C. A., Winter, K., Byhardt, R., Sause, W. T., Hanks, G. E., Russell, A. H., Rotman, M., Porter, A., McGowan, D. G., DelRowe, J. D. and Pilepich, M. V.: Androgen Suppression Plus Radiatoin vs. Radiation Alone for Patients with D1 (pN+) Adenocarcinoma of the Prostate (Results Based on a National Prospective Randomized Trial RTOG 85-31). Int J Radiat Oncol Biol Phys, 38(5):931-939, 1997. |
|
horm |
|
| gu/prostate |
Winter, K., Grignon, D., Pajak, T., Pilepich, M., Byhardt, R., Lawton, C., Gallagher, M., Mesic, J., Roach, M., Hanks, G., Coughlin, C. and Porter, A.: Subjective Pathology Tumor Grading: Impact on Design and Analysis of Radiation Therapy Oncology Group (RTOG) Prostate Trial 85-31. Proc Soc Clin Trials & Int'l Soc for Clin Biostatistics, Boston, MA, Controlled Clinc Trials, [18], pg. 186S-187S, Abs. #P124, 1997. |
|
stat/path |
|
| gu/prostate |
Winter, K., Grignon, D., Pajak, T., Pilepich, M., Byhardt, R., Lawton, C., Gallagher, M., Mesic, J., Roach, M., Hanks, G., Coughlin, C. and Porter, A.: The Need for Central Pathology Tumor Grading in Prostate Cancer Using Radiation Therapy Oncology Group (RTOG) 85-31. Proc Am Soc Thera Rad Oncol (ASTRO), Orlando, FL, Int J Radiat Oncol Biol Phys, [39], pg. 219, Abs. #1007, 1997. |
|
path |
|
| gu/prostate |
Grignon, D., Caplan, R., Sarkar, F., Lawton, C., Hammond, E., Pilepich, M., Forman, J., Mesic, J., Fu, K., Abrams, R., Pajak, T., Shipley, W. and Cox, J.: p53 Status and Prognosis of Locally Advanced Prostatic Adenocarcinoma: a Study Based on RTOG 86-10. J Natl Cancer Inst 89 (2):158-165, 1997. |
8610 |
path/horm |
|
| gu/prostate |
Pilepich, M., Caplan, R., Byhardt, R., Lawton, C., Gallagher, M., Mesic, J., Hanks, G., Coughlin, C., Porter, A., Shipley, W. and Grignon, D.: Phase III Trial of Androgen Suppression Using Goserelin in Unfavorable-Prognosis Carcinoma of the Prostate Treated with Definitive Radiotherapy: Report of RTOG Protocol 85-31. J Clin Oncol 15 (3):1013-1021, 1997. |
8531 |
horm |
|
| gu/prostate |
Grignon, D., Pajak, T., Winter, K., Pilepich, M., Byhardt, R., Lawton, C., Gallagher, M., Mesic, J., Roach, M., Hanks, G., Coughlin, C. and Porter, A.: Central Review vs. Institutional Gleason Grading and Its Impact on Phase III Clinical Trial Analysis: A Review of RTOG Protocol 85-31. Proceedings of United States and Canadian Acadamy of Pathology Meeting, Modern Path 10 :77a, 1997. |
8531 |
path |
|
| gu/bladder |
Heaney, J. A., Caplan, R. J., Tester, W. J., Porter, A., Pedersen, J., Wittington, R. and Byhardt, R.: Bladder Preservation in Patients Treated by a Neoadjuvant Combined Modality Program for Invasive Bladder Cancer: Preliminary Results of RTOG 88-02. American Urological Association, San Francisco, CA, J Urol, 151 (Number 5):[902], 1994. |
8802 |
surg/chemo |
|
| gu/bladder |
Tester, W., Porter, A., Heaney, J., Krall, J., Hammond, E., Pedersen, J., Wittington, R. and Asbell, S.: Neoadjuvant Combined Modality Program with Possible Organ Preservation for Invasive Bladder Cancer. Proc Am Soc Clin Oncol (ASCO), 10 165, [522], 1991. |
8802 |
chemo |
|
| gu/bladder |
Tester, W., Caplan, R., Heaney, J., Venner, P., Whittington, R., Byhardt, R., True, L. and Shipley, W.: Neoadjuvant Combined Modality Program with Selective Organ Preservation for Invasive Bladder Cancer: Results of RTOG Phase II Trial 88-02. J Clin Oncol, 14(1):119-126, 1996. |
8802 |
chemo/surg |
|
| gu/bladder |
Tester, W., Porter, A., Asbell, S., Coughlin, C., Heaney, J., Krall, J., Martz, K., Venner, P. and Hammond, E.: Combined Modality Program with Possible Organ Preservation for Invasive Bladder Carcinoma: Results of RTOG Protocol 85-12. Int J Radiat Oncol Biol Phys, 25(5):783-790, 1993. |
8512 |
chemo |
|
| gu/prostate |
Asbell, S. O., Caplan, R. J., Perez, C. A., Rubin, P., Doggett, R., Sause, W. T., Rotman, M., Emami, B., Shin, K. and Pilepich, M.: Impact of Surgical Staging in Evaluating the Radiotherapeutic Outcome in RTOG 77-06, A Phase III Study for T1b-T2N0M0 Prostatic Carcinoma. Proc Am Soc Thera Radiol Oncol (ASTRO), Miami Beach, FL, Int J Radiat Oncol Biol Phys, 32 (Supplement 1):143, [5], 1995. |
7706 |
surg |
|
| gu/prostate |
Shipley, W., Zietman, A., Hanks, G., Coen, J., Caplan, R., Won, M., Zagars, G. and Asbell, S.: Treatment Related Sequelae Following External Beam Radiation for Prostate Cancer: A Review with an Update in Patients with Stage T1 and T2 Tumors. J Urol, 152(November):1799-1805, 1994. |
|
lateff |
|
| gu/prostate |
Pilepich, M., Krall, J., Al-Sarraf, M., Roach, M. I., Doggett, R., Sause, W., Lawton, C., Abrams, R., Rotman, M., Rubin, P., Shipley, W. and Cox, J.: Androgen Ablation Adjuvant to Definitive Radiotherapy in Carcinoma of the Prostate: RTOG Experience -- Report on Protocol 86-10. Tokyo Symposium on Prostate Cancer, Tokyo, 1994. |
8610 |
horm |
|
| gu/prostate |
Watkins-Bruner, D., Scott, C., Lawton, C., DelRowe, J., Rotman, M., Buswell, L., Beard, C. and Cella, D.: RTOG's First Quality of Life Study - RTOG 90-20: A Phase II Trial of External Beam Radiation with Etanidazole for Locally Advanced Prostate Cancer. Int J Radiat Oncol Biol Phys, 33(4):901-906, 1995. |
9020 |
QOL |
|
| gu/prostate |
Porter, A., Order, S., Caplan, R., Gallagher, M., McGowan, D. and Lustig, R.: Report of a Multiinstitutional Phase I/II Study to Evaluate the Use of Strontium-89 Therapy in Metastatic Prostate Cancer - Radiation Therapy Oncology Group 88-21. Proc Am Soc Clin Oncol (ASCO), Dallas, Texas, Proc Am Soc Clin Oncol, 13 (March):446, [1540], 1994. |
8821 |
radiopharm |
|
| gu/prostate |
Pilepich, M., Caplan, R., Byhardt, R., Lawton, C., Gallagher, M., Mesic, J., Hanks, G., Coughlin, C. and Porter, A.: Phase III Trial of Androgen Suppression Using Goserelin in Unfavorable Prognosis Carcinoma of the Prostate Treated with Definitive Radiotherapy (Report of RTOG Protocol 85-31). Proc Am Soc Clin Oncol (ASCO), Los Angeles, CA, Proc Am Soc Clin Oncol 31st Annual Meeting, 14 (March 1995):239, [631*], 1995. |
8531 |
horm |
|
| gu/prostate |
Hanks, G., Hanlon, A., Schultheiss, T., Corn, B., Shipley, W. and Lee, W.: Early Prostate Cancer: The National Results of Radiation Treatment From the Patterns of Care and RTOG Studies with Prospects for Improvement with Conformal Radiation and Adjuvant Androgen Deprivation. J Urol, 152(5 Pt 2):1775-1780, 1994. |
|
|
|
| gu/prostate |
Shipley, W.: A Phase III Trial (RTOG 86-10) Comparing External Beam Irradiation plus Short-term Maximal Androgen Blockade with Radiation Therapy Alone for Locally Advanced Prostate Cancer. European Urology Supplement, Paris, Eur Urol, 26 (Supplement 1):26, 1994. |
8610 |
horm |
|
| gu/prostate |
Watkins-Bruner, D., Scott, C., Lawton, C., DelRowe, J., Rotman, M., Buswell, L., Beard, C. and Cella, D.: RTOG's First Quality of Life Study-RTOG 90-20 - A Phase II Trial of External Beam Radiation with Etanidazole for Locally Advanced Prostate Cancer. Proc Am Soc Thera Radiol Oncol (ASTRO), San Francisco, Int J Radiat Oncol Biol Phys, 30 (Supplement 1):193, [70], 1994. |
9020 |
QOL |
|
| gu/prostate |
Zhou, R., Hammond, E., Sause, W., Rubin, P., Emami, B., Pilepich, M., Asbell, S. and Parker, D.: Quantitation of Prostate-Specific Acid Phosphatase in Prostate Cancer: Reproducibility and Correlation with Subjective Grade. Mod Path, 7(4):440-448, 1994. |
|
path |
|
| gu/prostate |
Grignon, D., Caplan, R., Sakr, W., Porter, A., Doggett, R., John, M., Abrams, R. and Lawton, C.: Neuroendocrine (NE) Differentiation as a Prognostic Indicator in Locally Advanced Prostatic Cancer (PCa): A Study Based on RTOG Protocol 86-10. United States and Canadian Academy of Pathology Meeting, Toronto, Canada, Mod Path, 8 (1):76A, [436], 1995. |
8610 |
path/horm |
|
| gu/prostate |
Hanks, G. E., Perez, C. A., Kozar, M., Asbell, S. O., Pilepich, M. V. and Pajak, T. F.: PSA Confirmation of Cure at 10 years of T1B, T-2, N0, M0 Prostate Cancer Patients Treated in RTOG Protocol 77-06 with External Beam Irradiation. Int J Radiat Oncol Biol Phys, 30(2):289-292, 1994. |
7706 |
path |
|
| gu/prostate |
Grignon, D., Caplan, R., Sarkar, F., Forman, J., Mesic, J., Fu, K., Abrams, R. and Lawton, C.: p53 Suppressor Gene Mutations Predict for Failure Following Combined Neoadjuvant Total Androgen Ablation and External Beam Radiation Therapy for Locally Advanced Prostate Cancer: A Study Based on RTOG Protocol 86-10. American Urological Association Annual Meeting, Los Vegas, NV, J Urol, 153 (April 1995 Supplement):293A, 1995. |
8610 |
path/horm |
|
| gu/prostate |
Asbell, S., Caplan, R., Perez, C., Rubin, P., Doggett, R., Sause, W., Rotman, M., Emami, B., Shin, K. and Pilepich, M.: Impact of Surgical Staging in Evaluating the Radiotherapeutic Outcome in RTOG Phase III Study for T1b-T2N0M0 Prostatic Carcinoma. Proc Am Soc Clin Oncol (ASCO), Los Angeles, CA, Program/Proc Am Soc Clin Oncol 31st Annual Meeting, 14 (March 1995):512, [1681], 1995. |
7706 |
surg/QA |
|
| gu/prostate |
Lawton, C. A., Coleman, C. N., Buzydlowski, J. W., Forman, J. D., Marcial, V. A., DelRowe, J. D. and Rotman, M.: Results of a Phase II Trial of External Beam Radiation with Etanidazole (SR 2508) For the Treatment of Locally Advanced Prostate Cancer (RTOG Protocol 90-20). Int J Radiat Oncol Biol Phys, 36(3):673-680, 1996. |
9020 |
chemmod |
|
| gu/prostate |
Roach III, M., Caplan, R. J., Porter, A., John, M., Doggett, S., Sause, W. T., Lawton, C. A., Abrams, R., Rotman, M., Nelson, D. and Gallagher, M. J.: Combined Neoadjuvant Total Androgen Suppression (TAS) and External Beam Irradiation (XRT) Delay the Time to Biochemical Relapse (BCR) or Clinical Failure (CF) Compared to Radiation Alone for Locally Advanced Adenocarcinoma of the Prostate: The Radiation Oncology Group (RTOG) Phase III Randomized Trial 86-10. American Urological Association, San Francisco, CA, J Urol, 151 (Number 5):[590], 1994. |
8610 |
horm |
|
| gu/prostate |
Grignon, D., Caplan, R., Sarker, F., Forman, J., Mesic, J., Fu, K., Abrams, R. and Lawton, C.: p53 Suppressor Gene Status as a Predictor of Outcome in Patients with Locally Advanced Prostatic Anenocarcinoma (PCa) Treated by Radiation Therapy with and without Androgen Ablation Pre-Treatment: A Study Based on RTOG Protocol 86-10. United States and Canadian Acadamy of Pathology Meeting, Toronto, Canada, Mod Path, 8 (1):77A, [437], 1995. |
8610 |
path/horm |
|
| gu/prostate |
Shipley, W. U.: Phase III Trial of Androgen Suppression Before and During Radiation Therapy for Locally Advanced Prostatic Cancer: Abstract Report of RTOG 86-10. The Prostate Supplement, 5:2-3, 1994. |
8610 |
horm |
|
| gu/prostate |
Hanks, G., Asbell, S., Krall, J., Perez, C., Doggett, S., Rubin, P., Sause, W. and Pilepich, M.: Outcome for Lymph Node Dissection Negative T-1b, T-2 (A-2, B) Prostate Cancer Treated with External Beam Radiation Therapy in RTOG 77-06. Int J Radiat Oncol Biol Phys, 21:1099-1103, 1991. |
7706 |
other |
|
| gu/prostate |
Hanks, G., Krall, J., Pilepich, M., Asbell, S., Perez, C., Rubin, P., Sause, W. and Doggett, R.: Comparison of Pathologic and Clinical Evaluation of Lymph Nodes in Prostate Cancer: Implications of RTOG Data for Patient Management and Trial Design and Stratification. Int J Radiat Oncol Biol Phys, 23(2):293-298, 1992. |
7506, 7706 |
path/stat |
|
| gu/prostate |
Hanks, G., Perez, C., Kozar, M., Asbell, S., Pilepich, M. and Caplan, R.: Prostatic Specific Antigen Confirmation of Long-Term Cure of Prostate Cancer Treated by External Beam Radiation in the RTOG. Proc Am Soc Thera Radiol Oncol (ASTRO), New Orleans, LA, Int J Radiat Oncol Biol Phys, 27 192, [106], 1993. |
7506, 7706 |
path |
|
| gu/prostate |
Hanks, G. E., Krall, J. M., Hanlon, A. L., Asbell, S. O., Pilepich, M. V. and Owen, J. B.: Patterns of Care and RTOG Studies in Prostate Cancer: Long-Term Survival, Hazard Rate Observations, and Possibilities of Cure. Int J Radiat Oncol Biol Phys, 28(1):39-45, 1994. |
|
stat/meth |
|
| gu/prostate | |
